Pharmacokinetic–Pharmacodynamic Modelling: History and Perspectives
暂无分享,去创建一个
[1] R A Meiss,et al. Nonlinear force response of active smooth muscle subjected to small stretches. , 1984, The American journal of physiology.
[2] M. Danhof,et al. The Impact of Arteriovenous Concentration Differences on Pharmacodynamic Parameter Estimates , 1997, Journal of Pharmacokinetics and Biopharmaceutics.
[3] M Davidian,et al. Population pharmacokinetic/pharmacodynamic methodology and applications: a bibliography. , 1994, Biometrics.
[4] Steven L. Shafer,et al. Algorithms to rapidly achieve and maintain stable drug concentrations at the site of drug effect with a computer-controlled infusion pump , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[5] L B Sheiner,et al. Semiparametric approach to pharmacokinetic-pharmacodynamic data. , 1989, The American journal of physiology.
[6] L B Sheiner,et al. Pharmacodynamic model of tolerance: application to nicotine. , 1988, The Journal of pharmacology and experimental therapeutics.
[7] A. Perelson,et al. HIV-1 Dynamics in Vivo: Virion Clearance Rate, Infected Cell Life-Span, and Viral Generation Time , 1996, Science.
[8] W J Jusko,et al. Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. , 1998, Journal of pharmaceutical sciences.
[9] B. Efron,et al. Compliance as an Explanatory Variable in Clinical Trials , 1991 .
[10] John Anthony Bauer,et al. Application of Pharmacodynamic Modeling for Designing Time-Variant Dosing Regimens to Overcome Nitroglycerin Tolerance in Experimental Heart Failure , 1997, Pharmaceutical Research.
[11] G. Levy,et al. Apparent Potentiating Effect of a Second Dose of Drug , 1965, Nature.
[12] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[13] R. Furchgott,et al. The pharmacology of vascular smooth muscle. , 1955, Pharmacological reviews.
[14] M A Nowak,et al. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations. , 1997, Journal of theoretical biology.
[15] R C Boston,et al. Conversational SAAM--an interactive program for kinetic analysis of biological systems. , 1981, Computer programs in biomedicine.
[16] G. Levy,et al. Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.
[17] J. Mandema,et al. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. , 1995, The Journal of pharmacology and experimental therapeutics.
[18] G Levy,et al. Theoretical relationship between dose, elimination rate, and duration of pharmacologic effect of drugs. , 1965, Journal of Pharmacy and Science.
[19] S. M. Kupchan,et al. Tumor Inhibitors III. Monocrotaline, the Active Principle of Crotalaria spectabilis , 1964 .
[20] F. Frey,et al. Pharmacokinetics and pharmacodynamics of three different prednisolone prodrugs: effect on circulating lymphocyte subsets and function. , 1984, Journal of immunology.
[21] David B. Dunson,et al. Bayesian Data Analysis , 2010 .
[22] T. Theofanous,et al. Multiple-dose kinetics of oral anticoagulants: methods of analysis and optimized dosing. , 1973, Journal of pharmaceutical sciences.
[23] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.
[24] John Ferguson,et al. The Use of Chemical Potentials as Indices of Toxicity , 1939 .
[25] L B Sheiner,et al. Relationship between the pharmacokinetics and pharmacodynamics of procainamide , 1976, Clinical pharmacology and therapeutics.
[26] W J Jusko,et al. Pharmacodynamic modeling of time‐dependent transduction systems , 2001, Clinical pharmacology and therapeutics.
[27] E. Ekblad,et al. A model eliciting transient responses. , 1984, The American journal of physiology.
[28] G. Segre,et al. Kinetics of interaction between drugs and biological systems. , 1968, Il Farmaco; edizione scientifica.
[29] M A Nowak,et al. Virus dynamics and drug therapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[30] D Verotta,et al. Concepts, properties, and applications of linear systems to describe distribution, identify input, and control endogenous substances and drugs in biological systems. , 1996, Critical reviews in biomedical engineering.
[31] G Levy,et al. Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.
[32] J. Black,et al. Operational models of pharmacological agonism , 1983, Proceedings of the Royal Society of London. Series B. Biological Sciences.
[33] Lewis B. Sheiner,et al. A general conceptual model for non-steady state pharmacokinetic/Pharmacodynamic data , 2006, Journal of Pharmacokinetics and Biopharmaceutics.
[34] W J Jusko,et al. Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.
[35] D. Verotta,et al. A general solution for nonparametric control of a linear system using computer-controlled infusion pumps , 1999, IEEE Transactions on Biomedical Engineering.
[36] William J. Jusko,et al. A pharmacodynamic model for cell-cycle-specific chemotherapeutic agents , 1973, Journal of Pharmacokinetics and Biopharmaceutics.
[37] L B Sheiner,et al. Population pharmacokinetics/dynamics. , 1992, Annual review of pharmacology and toxicology.
[38] Richard P. Lewis,et al. Pharmacokinetics of digoxin: Relationship between response intensity and predicted compartmental drug levels in man , 1979, Journal of Pharmacokinetics and Biopharmaceutics.
[39] W J Jusko,et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity , 1991, Clinical pharmacology and therapeutics.
[40] R J Tallarida. Receptor theories and quantitative effect versus dose-concentration relationship. , 1984, Drug metabolism reviews.
[41] J J DiStefano,et al. Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations. , 1984, The American journal of physiology.
[42] William J Jusko,et al. Diversity of mechanism-based pharmacodynamic models. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[43] M W Fischman,et al. Kinetics of cocaine distribution, elimination, and chronotropic effects , 1985, Clinical pharmacology and therapeutics.
[44] R Byck,et al. Kinetics of drug effect by distributed lags analysis: An application to cocaine , 1982, Clinical pharmacology and therapeutics.
[45] J. L. Steimer,et al. Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .
[46] W. Jusko,et al. Gender‐based effects on methylprednisolone pharmacokinetics and pharmacodynamics , 1993, Clinical pharmacology and therapeutics.
[47] L B Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models , 1986, Clinical pharmacology and therapeutics.
[48] Aaron Tucker,et al. A Bibliography. , 1902, British medical journal.
[49] William J. Jusko,et al. Second generation model for prednisolone pharmacodynamics in the rat , 1989, Journal of Pharmacokinetics and Biopharmaceutics.
[50] L B Sheiner,et al. Kinetics of pharmacologic response. , 1982, Pharmacology & therapeutics.
[51] Davide Verotta,et al. Models and estimation methods for clinical HIV-1 data , 2005 .
[52] W J Jusko,et al. Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects , 1989, Clinical pharmacology and therapeutics.
[53] Hulin Wu,et al. A Comparison Study of Models and Fitting Procedures for Biphasic Viral Dynamics in HIV‐1 Infected Patients Treated with Antiviral Therapies , 2000, Biometrics.
[54] D Verotta,et al. Chronopharmacokinetics of nicotine , 1996, Clinical pharmacology and therapeutics.
[55] G Levy,et al. Pharmacologic target‐mediated drug disposition , 1994, Clinical pharmacology and therapeutics.
[56] J J DiStefano,et al. Multiexponential, multicompartmental, and noncompartmental modeling. I. Methodological limitations and physiological interpretations. , 1984, The American journal of physiology.
[57] L B Sheiner,et al. Semiparametric models for antagonistic drug interactions. , 1994, Journal of applied physiology.
[58] A S Perelson,et al. Modeling plasma virus concentration during primary HIV infection. , 2000, Journal of theoretical biology.
[59] M Danhof,et al. Relevance of arteriovenous concentration differences in pharmacokinetic-pharmacodynamic modeling of midazolam. , 1998, The Journal of pharmacology and experimental therapeutics.
[60] M Danhof,et al. A system approach to pharmacodynamics. III: An algorithm and computer program, COLAPS, for pharmacodynamic modeling. , 1991, Journal of pharmaceutical sciences.
[61] G Levy,et al. Multicompartment pharmacokinetic models and pharmacologic effects. , 1969, Journal of pharmaceutical sciences.
[62] L B Sheiner,et al. Simultaneous Modeling of Pharmacokinetics and Pharmacodynamics with a Nonparametric Pharmacodynamic Model , 1984, Clinical pharmacology and therapeutics.
[63] L. Sheiner,et al. Modelling of individual pharmacokinetics for computer-aided drug dosage. , 1972, Computers and biomedical research, an international journal.
[64] L B Sheiner,et al. Computer-aided long-term anticoagulation therapy. , 1969, Computers and biomedical research, an international journal.
[65] T. Schnider,et al. Expanding clinical applications of population pharmacodynamic modelling. , 1998, British journal of clinical pharmacology.
[66] G Levy,et al. Mechanism‐based pharmacodynamic modeling , 1994, Clinical pharmacology and therapeutics.
[67] N H Holford,et al. Concepts and usefulness of pharmacokinetic‐pharmacodynamic modelling , 1990, Fundamental & clinical pharmacology.
[68] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: an improved algorithm , 1987, Comput. Appl. Biosci..
[69] James C. Scott,et al. Testing computer-controlled infusion pumps by simulation. , 1988, Anesthesiology.
[70] Berend Oosterhuis,et al. Pharmacokinetic‐pharmacodynamic modeling of terbutaline bronchodilation in asthma , 1986, Clinical pharmacology and therapeutics.
[71] Davide Verotta,et al. An inequality-constrained least-squares deconvolution method , 1989, Journal of Pharmacokinetics and Biopharmaceutics.
[72] H Wu,et al. Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.
[73] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[74] R. Evans,et al. The steroid and thyroid hormone receptor superfamily. , 1988, Science.
[75] W J Jusko,et al. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. , 1998, Journal of pharmaceutical sciences.
[76] William J. Jusko,et al. Receptor-mediated pharmacodynamics of prednisolone in the rat , 1986, Journal of Pharmacokinetics and Biopharmaceutics.
[77] L. Paalzow,et al. Relation between morphine pharmacokinetics and analgesia , 1978, Journal of Pharmacokinetics and Biopharmaceutics.
[78] L B Sheiner,et al. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. , 1996, The American journal of physiology.
[79] E. J. Ariëns. Molecular pharmacolōgy : the mode of action of biologically active compounds , 1964 .
[80] Vito Volterra,et al. Theory of Functionals and of Integral and Integro-Differential Equations , 2005 .
[81] Daniel E. Salazar,et al. Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[82] B. O’Malley,et al. Mechanisms of action of steroid hormones. , 1971, The New England journal of medicine.
[83] V. Marmarelis. Identification of nonlinear biological systems using laguerre expansions of kernels , 1993, Annals of Biomedical Engineering.
[84] J. Wagner,et al. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. , 1968, Journal of theoretical biology.
[85] A S Perelson,et al. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. , 1998, Journal of theoretical biology.
[86] M A Nowak,et al. Coexistence and competition in HIV infections. , 1992, Journal of theoretical biology.
[87] M A Nowak,et al. Mathematical biology of HIV infections: antigenic variation and diversity threshold. , 1991, Mathematical biosciences.
[88] Davide Verotta,et al. Volterra Series in Pharmacokinetics and Pharmacodynamics , 2003, Journal of Pharmacokinetics and Pharmacodynamics.
[89] Lewis B. Sheiner,et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarine , 1979 .
[90] Timothy J. O'Leary,et al. Predicting oral anticoagulant response using a pharmacodynamic model , 2006, Annals of Biomedical Engineering.
[91] L. Paalzow,et al. Acute tolerance to furosemide diuresis in humans. Pharmacokinetic-pharmacodynamic modeling. , 1985, The Journal of pharmacology and experimental therapeutics.
[92] R M May. Nonlinearities and Complex Behavior in Simple Ecological and Epidemiological Models a , 1987, Annals of the New York Academy of Sciences.
[93] A Sibbald,et al. A pharmacodynamic model for pancuronium. , 1978, British journal of anaesthesia.
[94] Davide Verotta,et al. Non-linear dynamics models characterizing long-term virological data from AIDS clinical trials. , 2002, Mathematical biosciences.
[95] T J O'Leary,et al. Evaluation of a computer‐assisted method for individualized anticoagulation: Retrospective and prospective studies with a pharmacodynamic model , 1982, Clinical pharmacology and therapeutics.
[96] M Danhof,et al. Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam. , 1999, The Journal of pharmacology and experimental therapeutics.
[97] Carl de Boor,et al. A Practical Guide to Splines , 1978, Applied Mathematical Sciences.
[98] Lewis B. Sheiner,et al. Semiparametric analysis of non-steady-state pharmacodynamic data , 2005, Journal of Pharmacokinetics and Biopharmaceutics.
[99] L B Sheiner,et al. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. , 1982, Journal of pharmaceutical sciences.
[100] Yangxin Huang,et al. Mechanistic PK/PD Modeling of Antiretroviral Therapies in AIDS Clinical Trials , 2004 .
[101] Peter Veng-Pedersen,et al. Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions , 1991, Journal of Pharmacokinetics and Biopharmaceutics.
[102] P H van der Graaf,et al. A set-point model with oscillatory behavior predicts the time course of 8-OH-DPAT-induced hypothermia. , 2001, American journal of physiology. Regulatory, integrative and comparative physiology.
[103] Wojciech Krzyzanski,et al. Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.
[104] J Urquhart,et al. Contending paradigms for the interpretation of data on patient compliance with therapeutic drug regimens. , 1998, Statistics in medicine.
[105] L B Sheiner,et al. Pharmacokinetic‐pharmacodynamic modeling of caffeine: Tolerance to pressor effects , 1993, Clinical pharmacology and therapeutics.
[106] G. Levy,et al. RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.
[107] C G Brook,et al. The relationship between endogenous testosterone and gonadotrophin secretion , 1993, Clinical Endocrinology.